Stock RO ROCHE HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

News Roche Holding AG Swiss Exchange

Equities

RO

CH0012032113

Real-time Estimate Cboe Europe
Other stock markets
 03:43:43 2024-04-18 am EDT 		5-day change 1st Jan Change
237.5 CHF +0.04% Intraday chart for Roche Holding AG -2.22% -9.03%
Apr. 17 Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial MT
Apr. 17 Roche: positive phase III results in MS CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial
MT
Roche: positive phase III results in MS
CF
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
BU
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)
CI
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating
ZD
Roche: positive phase III data in lymphoma
CF
Roche's Late-stage Trial for Columvi Antibody Meets Primary Survival Endpoint in B-cell Lymphoma
MT
Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial
DJ
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
BU
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating
ZD
Swiss Market Index Falls as ECB Signals June Rate Cut
MT
ROCHE HOLDINGS AG : Berenberg reiterates its Neutral rating
ZD
Roche: designation for Alzheimer's test
CF
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review
DJ
Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation
MT
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis
CI
Swiss Market Index Little Changed; Barry Callebaut Shines on Revenue Jump
MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark
MT
Roche: CE mark for Enhertu companion test
CF
Novartis to cut 680 jobs in product development
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROG Stock
  4. RO Stock
  5. News Roche Holding AG